表紙
市場調查報告書
商品編碼
979398

肝癌-至2029年的流行病學預測

Hepatocellular Carcinoma - Epidemiology Forecast to 2029

出版日期: | 出版商: GlobalData | 英文 62 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

肝細胞癌(HCC)是原發性肝癌的一種常見類型,起源於肝臟中的肝細胞。 HCC的死亡率很高,佔所有原發性肝癌的75-90%,使其成為全球第三大癌症死亡率的主要原因(El-Serag和Rudolph,2007; Altekruse,McGlynn和Reichman,2009; Lafaro,Demirjian和Pawlik,2015年;美國癌症治療中心,2020年)。 肝癌各種分期系統分類,例如巴塞羅那臨床肝癌(BCLC)階段和Child Pugh階段。 肝癌的主要危險因素是B型肝炎病毒(HBV)感染,C型肝炎病毒(HCV)感染和酗酒(Lafaro,Demirjian和Pawlik,2015)。

本報告提供8大市場(美國、法國、德國、義大利、西班牙、英國、日本、中國)的從2019年到2029年的肝癌發病趨勢與危險因素等。

目錄

第1章 目錄

  • 表格清單
  • 圖表清單

第2章 肝癌:摘要整理

  • 促進要素
  • 相關報告
  • 今後的報告

第3章 流行病學

  • 病的背景
  • 危險因素和合併症
  • 世界的趨勢及歷史的趨勢
  • 預測調查手法
    • 來源
    • 預測的前提條件與方法
    • HCC的診斷發病數量
    • 各BCLC階段HCC的診斷發病數量
    • Child Pugh Stage的HCC診斷發病數量
    • 各危險因素HCC診斷發病數量
    • 各肝硬化對非肝硬化的各HCC診斷發病數量
    • 各生物標記AFPHCC診斷發病數量
    • HCC的5年的診斷盛行率
    • 各BCLC階段HCC的到目前為止確診的盛行率
  • HCC的流行病學預測,2019∼2029年
    • HCC的診斷發病數量
    • HCC的性別診斷發病數量
    • HCC的各年齡診斷發病數量
    • 各BCLC階段HCC診斷發病數量
    • Child Pugh 由於Stage的HCC診斷發病數量
    • 各危險因素HCC診斷發病數量
    • 各肝硬化對非肝硬化的各HCC診斷發病數量
    • 各生物標記AFPHCC診斷發病數量
    • HCC的5年的診斷盛行率
    • 各BCLC階段HCC的到目前為止確診的盛行率
  • 討論
    • 流行病學預測的洞察
    • COVID-19的影響
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考文件
  • 關於作者
    • 流行病學者
    • 檢閱者
    • 治療分析及流行病學的全球董事
    • 醫療保健事業及策略的全球負責人兼EVP
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明
目錄
Product Code: GDHCER261-20

Hepatocellular Carcinoma - Epidemiology Forecast to 2029

Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC has a high mortality rate and accounts for 75-90% of all primary liver cancers, making it the third leading cause of cancer mortality worldwide (El-Serag and Rudolph, 2007; Altekruse, McGlynn and Reichman, 2009; Lafaro, Demirjian and Pawlik, 2015; Cancer Treatment Centers of America, 2020). HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages. The major risk factors for HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcohol abuse (Lafaro, Demirjian and Pawlik, 2015).

Cirrhosis is present in 80-90% of HCC patients and is crucial in the development of HCC. HCC is more common in men than women, averaging between two to four times as many cases in men than in women (El-Serag and Rudolph, 2007; Altekruse, McGlynn and Reichman, 2009). This could be due to men being more likely to be infected with HBV and HCV, consume alcohol, smoke cigarettes, or have increased iron levels (El-Serag and Rudolph, 2007).

In 2019, the 8MM combined had 259,561 diagnosed incident cases of HCC in both sexes for ages 18 years and older. In 2019, Urban China accounted for the majority of these cases, with 154,032 diagnosed incident cases, while the UK accounted for the fewest cases, with 5,700 cases. GlobalData epidemiologists forecast the diagnosed incident cases of HCC to increase to 343,761 cases in 2029 in the 8MM at an Annual Growth Rate (AGR) of 3.24% during the forecast period.

Scope

  • The Hepatocellular Carcinoma (HCC) Epidemiology Report provides an overview of the risk factors and the global and historical trends for HCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets from 2019-2029.
  • The diagnosed incident cases of HCC are further segmented by sex and age (18 years and older), BCLC Stage (stage A, stage B, stage C, and stage D), Child Pugh stage (Child Pugh stage A, Child Pugh stage B, and Child Pugh stage C), HCC risk factors (HBV, HCV, non-alcoholic steatohepatitis [NASH] or non-alcoholic fatty liver disease [NAFLD], and alcohol use), cirrhotic and non-cirrhotic HCC, and biomarkers (Alpha-fetoprotein [AFP], >400ng/mL). Additionally, the report includes the all-time diagnosed prevalent cases of HCC by BCLC stage.
  • The HCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The HCC Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HCC market.
  • Quantify patient populations in the global HCC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HCC therapeutics in each of the markets covered.
  • Understand magnitude of HCC by stage at diagnosis, BCLC stage, Child Pugh stage, risk factors and biomarkers.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Hepatocellular Carcinoma: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Incident Cases of HCC
    • 3.4.4 Diagnosed Incident Cases of HCC by BCLC Stage
    • 3.4.5 Diagnosed Incident Cases of HCC by Child Pugh Stage
    • 3.4.6 Diagnosed Incident Cases by HCC Risk Factors
    • 3.4.7 Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-cirrhotic HCC
    • 3.4.8 Diagnosed Incident Cases of HCC by Biomarker AFP
    • 3.4.9 Five-Year Diagnosed Prevalent Cases of HCC
    • 3.4.10 All-Time Diagnosed Prevalent Cases of BCLC by Stage
  • 3.5 Epidemiological Forecast for HCC, 2019-2029
    • 3.5.1 Diagnosed Incident Cases of HCC
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of HCC
    • 3.5.3 Age-Specific Diagnosed Incident Cases of HCC
    • 3.5.4 Diagnosed Incident Cases of HCC by BCLC Stage
    • 3.5.5 Diagnosed Incident Cases of HCC by Child Pugh Stage
    • 3.5.6 Diagnosed Incident Cases of HCC by Risk Factors
    • 3.5.7 Diagnosed Incident Cases by Cirrhotic Versus Non-cirrhotic HCC
    • 3.5.8 Diagnosed Incident Cases of HCC by Biomarker AFP
    • 3.5.9 Five-Year Diagnosed Prevalent Cases of HCC
    • 3.5.10 All-Time Diagnosed Prevalent Cases of HCC by BCLC Stage
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for HCC

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of HCC (N), Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of HCC (N), Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of HC